Published in N Engl J Med on March 13, 1980
Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction. Br J Clin Pharmacol (1982) 0.91
Amiodarone for refractory cardiac arrhythmias: 10-year study. CMAJ (1986) 0.89
Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group. Postgrad Med J (1984) 0.85
Molecular modeling, docking and ADMET studies towards development of novel Disopyramide analogs for potential inhibition of human voltage gated sodium channel proteins. Bioinformation (2012) 0.81
A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction. Br J Clin Pharmacol (1982) 0.78
Cardiovascular effects of acute normovolemic hemodilution in rats with disopyramide-induced myocardial depression. Basic Res Cardiol (1990) 0.76
Acute cardiac failure and hepatic ischemia induced by disopyramide phosphate. Yale J Biol Med (1981) 0.76
Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure. Br J Clin Pharmacol (1985) 0.75
Severe hypoglycemia associated with disopyramide. West J Med (1983) 0.75
Haemodynamic effects of class I antiarrhythmic agents. Drugs (1985) 0.75
Comparative hemodynamics of antiarrhythmic drugs. Cardiovasc Drugs Ther (1990) 0.75
The coronary care unit. New perspectives and directions. JAMA (1967) 6.31
Results of a second-opinion trial among patients recommended for coronary angiography. JAMA (1992) 5.23
Electrical reversion of cardiac arrhythmias. Br Heart J (1967) 3.94
Approaches to sudden death from coronary heart disease. Circulation (1971) 3.58
"Let me see if i have this right...": words that help build empathy. Ann Intern Med (2001) 2.78
Models for the evaluation of pre-hospital coronary care. Am J Cardiol (1969) 2.68
Unresolved problems in coronary care. Am J Cardiol (1967) 2.59
Use of the acute cardiac ischemia time-insensitive predictive instrument (ACI-TIPI) to assist with triage of patients with chest pain or other symptoms suggestive of acute cardiac ischemia. A multicenter, controlled clinical trial. Ann Intern Med (1998) 2.58
Neural activity and ventricular fibrillation. N Engl J Med (1976) 2.21
Sleep and ventricular premature beats. Circulation (1973) 2.10
Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction. J Am Coll Cardiol (1998) 2.02
Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials. Lancet (1981) 2.01
Comparison of ventricular ectopic activity during 24-hour monitoring and exercise testing in patients with coronary heart disease. N Engl J Med (1975) 1.98
Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation (1982) 1.93
Lupus-like syndrome induced by procainamide. Am J Cardiol (1967) 1.86
Side effects from amiodarone. Am Heart J (1991) 1.74
Cardioversion and digitalis. II. Clinical studies. Circulation (1966) 1.57
Side effects and complications of amiodarone therapy. Am Heart J (1985) 1.54
Sudden cardiac death: the major challenge confronting contemporary cardiology. Am J Cardiol (1979) 1.52
The nuclear-arms race and the physician. N Engl J Med (1981) 1.44
Results of a second-opinion program for coronary artery bypass graft surgery. JAMA (1987) 1.42
An appeal for nuclear sanity: an open letter to: Prime Minister Atal Behari Vajpayee of India: Prime Minister Nawaz Sharif of Pakistan. JAMA (1998) 1.40
Spontaneous reversion of ventricular fibrillation. Am Heart J (1988) 1.40
Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol (1982) 1.37
The use of quinidine in cardioversion. Am J Cardiol (1967) 1.37
Neural and psychologic mechanisms and the problem of sudden cardiac death. Am J Cardiol (1977) 1.30
Long-term use of procaine amide following acute myocardial infarction. Circulation (1973) 1.29
Detection and sizing of acute myocardial infarcts with 99mTc (Sn) tetracycline. N Engl J Med (1974) 1.28
An analysis of the cost effectiveness of the implantable defibrillator. Circulation (1990) 1.26
Lidocaine in acute myocardial infarction. Am Heart J (1968) 1.26
Occurrence of ventricular arrhythmias with exercise as compared to monitoring. Circulation (1971) 1.25
Cardioversion and digitalis drugs: changed threshold to electric shock in digitalized animals. Circ Res (1965) 1.25
Exercise stress testing for exposure of cardiac arrhythmia. Prog Cardiovasc Dis (1974) 1.24
Retirement and coronary mortality. Lancet (1980) 1.23
Effects of chronic depletion of potassium and magnesium upon the action of acetylstrophanthidin on the heart. Am J Cardiol (1966) 1.22
Nobel Peace Prize lecture. A prescription for hope. N Engl J Med (1986) 1.16
Assessment of myocardial contractility from ventricular pressure recordings. Cardiovasc Res (1971) 1.14
Cardioversion and defibrillation. Am Heart J (1980) 1.13
Variant angina pectoris. N Engl J Med (1970) 1.13
Effect of stellectomy and vagotomy on ventricular refractoriness in dogs. Circ Res (1977) 1.13
Myocardial infarction following coronary ligation in dogs. Hemodynamic effects of isoproterenol and acetylstrophanthidin. Circ Res (1967) 1.11
Relationship between sympathetic neural activity, coronary dynamics, and vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion. Am Heart J (1983) 1.09
Cooperation not confrontation: the imperative of a nuclear age. The message from Budapest. JAMA (1985) 1.09
Duration of hospital stay following acute myocardial infarction. Am J Cardiol (1969) 1.09
Ventricular vulnerability during sympathetic stimulation: role of heart rate and blood pressure. Cardiovasc Res (1974) 1.09
Psychophysiologic factors in sudden cardiac death. Am J Psychiatry (1980) 1.09
Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J (1983) 1.08
Intrinsic sympathomimetic activity and the effects of beta-adrenergic blocking drugs on vulnerability to ventricular fibrillation. J Am Coll Cardiol (1983) 1.08
Ventricular premature beats and anatomically defined coronary heart disease. Am J Cardiol (1977) 1.08
The effect of vagus nerve stimulation upon vulnerability of the canine ventricle: role of sympathetic-parasympathetic interactions. Circulation (1975) 1.08
Mental stress, arrhythmias and sudden death. Am J Med (1982) 1.07
Acute oral testing for determining antiarrhythmic drug efficacy. I. Quinidine. Am J Cardiol (1976) 1.07
Right coronary artery stenosis: an independent predictor of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol (1995) 1.06
Roles of psychologic stress and autonomic nervous system changes in provocation of ventricular premature complexes. Am J Cardiol (1978) 1.06
Differing mechanisms for ventricular vulnerability during coronary artery occlusion and release. Am Heart J (1976) 1.05
Chest thump for reverting ventricular tachycardia. N Engl J Med (1970) 1.04
Psychologic stress and threshold for repetitive ventricular response. Science (1973) 1.03
A medical prescription for survival. Lancet (1985) 1.02
Drug-associated diarrhoea as a potential reservoir for hospital infections. Lancet (1974) 1.02
Nitrous oxide as an analgesic in acute myocardial infarction. JAMA (1976) 1.02
The concept of precoronary care. Mod Concepts Cardiovasc Dis (1970) 1.01
Protective effect of verapamil on vulnerability to ventricular fibrillation during myocardial ischaemia and reperfusion. Cardiovasc Res (1980) 1.01
Aggravation of arrhythmia induced with antiarrhythmic drugs during electrophysiologic testing. Am Heart J (1985) 1.01
Coronary and precoronary care. Am J Med (1969) 0.98
Sudden cardiac death -- 1978. Circulation (1979) 0.95
The coronary care unit. Am J Cardiol (1968) 0.95
Health-manpower needs. N Engl J Med (1978) 0.95
Safety of maximal exercise testing in patients at high risk for ventricular arrhythmia. Circulation (1984) 0.95
Management of patients with malignant ventricular arrhythmias. Am J Cardiol (1977) 0.95
Influence of vagal tone on stellectomy-induced changes in ventricular electrical stability. Am J Physiol (1978) 0.94
Electrical conversion of atrial flutter to atrial fibrillation. Flutter mechanism in man. Br Heart J (1972) 0.94
Acute psychological disturbances preceding life-threatening ventricular arrhythmias. JAMA (1981) 0.93
Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med (1997) 0.93
Antiarrhythmic drug therapy for sporadic ventricular ectopic arrhythmias. Circulation (1974) 0.92
Delayed myocardial ischemia induced by anger. Circulation (1987) 0.92
A vulnerable period for ventricular tachycardia following myocardial infarction. Cardiovasc Res (1968) 0.92
Basis for recurring ventricular fibrillation in the absence of coronary heart disease and its management. N Engl J Med (1976) 0.91
The effect of caffeine on ventricular ectopic activity in patients with malignant ventricular arrhythmia. Arch Intern Med (1989) 0.91
Influence of glucose, insulin, and potassium on vulnerability to ventricular fibrillation in the canine heart. Circ Res (1978) 0.90
Implanted standby defibrillators. Circulation (1972) 0.90
Digitalization of the myocardium in the intact animal by direct coronary arterial drug administration. II. Relation of the rate of administration to myocardial concentration and toxicity. Am J Cardiol (1970) 0.89
Vulnerability to ventricular fibrillation during acute coronary arterial occlusion and release. Am J Cardiol (1975) 0.89
Artificial cardiac pacemakers. 3. N Engl J Med (1970) 0.89
Monitoring for serious arrhythmias and high risk of sudden death. Circulation (1975) 0.89
Repetitive extrasystole as an index of vulnerability to ventricular fibrillation. Am J Physiol (1976) 0.88
Amiodarone therapy in symptomatic, sustained refractory atrial and ventricular tachyarrhythmias. Am Heart J (1981) 0.88
Changes in left atrial size in patients with lone atrial fibrillation. Clin Cardiol (1991) 0.87
Energy requirement for defibrillation of a markedly overweight patient. Circulation (1978) 0.87
Effect of posterior hypothalamic stimulation on ventricular fibrillation threshold. Am J Physiol (1975) 0.87
Mexiletine for ventricular arrhythmias. Am J Cardiol (1981) 0.86
Correlation of the electrical and mechanical changes in the dog heart during progressive digitalization. Circ Res (1971) 0.86
Effect of hypokalemia on susceptibility to ventricular fibrillation in the normal and ischemic canine heart. Am Heart J (1986) 0.86
Correlation of the electrophysiologic action of digoxin with serum digoxin concentration. J Pharmacol Exp Ther (1972) 0.86